This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients.
We care about your feedback. Let us know how we can improve your CancerCompass experience.